Intravenous immunoglobulin for prophylaxis and therapy of sepsis

Current Opinion in Critical Care

Volumn 7, Issue 5, 2001, Pages 354-361

  Werdan, Karl ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SHOCK, SEPTIC;

EID: 0035169276     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200110000-00007     Document Type: Review

References (54)

1. Clinically-oriented therapies in sepsis: A review
2. Treating patients with severe sepsis
3. Intravenous immunoglobulins and granulocyte colony-stimulating factor for the management of infection in intensive care units
4. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiencies
5. Supplemental immune globulins in sepsis
6. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins
7. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product
8. Efficacy and potential clinical application of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion
9. Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens
10. Release of gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5
11. Influence of human anti-lipopolysaccharide immunoglobulins on tissue distribution and clearance of lipopolysaccharide in rats
12. High doses of intravenous immunoglobulin G enhance Kupffer cell phagocytic function during the late phase of sepsis and endotoxemia in rats
13. Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram-negative septicemia
14. Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants?
15. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation
16. The role of complement in the acquired immune response
17. The role of complement cascade in sepsis
18. Protective effects of C5a blockade in sepsis
19. A new small molecule C5a receptor antagonist inhibits the reverse-passive arthus reaction and endotoxic shock in rats
20. Study of the protective effects of hyperimmune immunoglobulins G and M against endotoxin in mice and rats
21. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study
22. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins
23. Reduced incidence of postoperative infections after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched immunoglobulin preparation in anergic patients undergoing cardiac surgery
24. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model
25. In vitro immunoglobulin response of fetal B-cells is influenced by perinatal infections and antibiotic treatment: A study in preterm infants
26. Sepsis masquerading as reaction to gammaglobulin
27. Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Library)
28. Supplemental immunoglobulin therapy in sepsis and septic shock-comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo: Protocol of a multicenter, randomized, prospective, double-blind trial
29. Polyvalent immune globulins
30. Anti-endotoxin therapy for fulminant meningococcal septicaemia: Pilot study
31. Meningococcal disease
32. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: Case report and review
33. Toxic shock syndrome toxin-1 (TSST-1) antibody levels in burned children
34. Intravenous immunoglobulin for suspected or subsequently proven neonatal infection (Cochrane Review)
35. The rote of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis
36. Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis
37. Levels of antibodies to endotoxin and cytokine release in patients with severe trauma: Does posttraumatic dysergy contribute to organ failure?
38. Use of immune globulin intravenous (human) to prevent infection in the multiple trauma patient
39. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants
40. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G
41. Additional confirmation of the lack of effect of intravenous immunoglobulin in the prevention of neonatal infection
42. Prophylactic use of immunoglobulins in cardiac surgery
43. Immunoglobulins in inflammation. Consensus-assisted Protocol Development and Discussion Forum of a Study Protocol 'Adjuvant Treatment of Mediastinitis with Immuno-globulins (Pentaglobin) after Cardiac Surgery (ATMI)'
44. Improved outcome of APACHE II score-defined escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared to 1988-1990: The ESSICS-study pilot project
45. Use of intravenous immunoglobulins as an adjunct in the conservative management of chylothorax
46. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change
47. For the Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) Investigators: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy
48. Intravenous immune globulin in the therapy of peripartum cardiomyopathy
49. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis
50. High-dose intravenous IgG for treatment of severe surgical infections
51. Treatment of Gram-negative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial
52. Letters to the editor
53. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial